JP2000510113A - ＴＮＦＲ―Ｉｇによる喘息の治療 - Google Patents

ＴＮＦＲ―Ｉｇによる喘息の治療

Info

Publication number: JP2000510113A
Authority: JP; Japan
Prior art keywords: tnfr; igg; preparation; protein; asthma
Prior art date: 1996-05-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP09539522A

Other languages

English (en)

Japanese (ja)

Inventor

レンツェッティ，ルイス・マーチン

Original Assignee

エフ・ホフマン―ラロシュアーゲー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-08

Filing date

1997-05-02

Publication date

2000-08-08

1997-05-02 Application filed by エフ・ホフマン―ラロシュアーゲー filed Critical エフ・ホフマン―ラロシュアーゲー

2000-08-08 Publication of JP2000510113A publication Critical patent/JP2000510113A/ja

Status Pending legal-status Critical Current

Links

208000006673 asthma Diseases 0.000 title claims abstract description 66
238000011282 treatment Methods 0.000 title abstract description 26
238000000034 method Methods 0.000 claims abstract description 54
239000000203 mixture Substances 0.000 claims abstract description 53
238000004519 manufacturing process Methods 0.000 claims abstract description 17
239000003814 drug Substances 0.000 claims abstract description 15
108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 14
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 14
102000023732 binding proteins Human genes 0.000 claims abstract description 10
108091008324 binding proteins Proteins 0.000 claims abstract description 10
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract 6
102000005962 receptors Human genes 0.000 claims abstract 3
108020003175 receptors Proteins 0.000 claims abstract 3
238000002360 preparation method Methods 0.000 claims description 44
108090000623 proteins and genes Proteins 0.000 claims description 36
102000004169 proteins and genes Human genes 0.000 claims description 35
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 19
230000000694 effects Effects 0.000 claims description 19
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 18
239000007921 spray Substances 0.000 claims description 15
238000002347 injection Methods 0.000 claims description 12
239000007924 injection Substances 0.000 claims description 12
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 11
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 9
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 9
229950006780 n-acetylglucosamine Drugs 0.000 claims description 9
108020001507 fusion proteins Proteins 0.000 claims description 8
102000037865 fusion proteins Human genes 0.000 claims description 8
239000007788 liquid Substances 0.000 claims description 8
229920001542 oligosaccharide Polymers 0.000 claims description 8
150000002482 oligosaccharides Chemical class 0.000 claims description 8
125000005629 sialic acid group Chemical group 0.000 claims description 7
230000037396 body weight Effects 0.000 claims description 4
230000004927 fusion Effects 0.000 claims description 4
239000007922 nasal spray Substances 0.000 claims 1
229940097496 nasal spray Drugs 0.000 claims 1
239000000668 oral spray Substances 0.000 claims 1
229940041678 oral spray Drugs 0.000 claims 1
210000004027 cell Anatomy 0.000 description 54
241001465754 Metazoa Species 0.000 description 29
235000018102 proteins Nutrition 0.000 description 28
208000024891 symptom Diseases 0.000 description 27
239000000443 aerosol Substances 0.000 description 26
238000010253 intravenous injection Methods 0.000 description 24
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 23
229960003957 dexamethasone Drugs 0.000 description 23
210000000440 neutrophil Anatomy 0.000 description 23
241000700198 Cavia Species 0.000 description 22
150000001720 carbohydrates Chemical class 0.000 description 20
230000002829 reductive effect Effects 0.000 description 20
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 19
102400000096 Substance P Human genes 0.000 description 19
101800003906 Substance P Proteins 0.000 description 19
235000014633 carbohydrates Nutrition 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
210000003979 eosinophil Anatomy 0.000 description 18
210000004969 inflammatory cell Anatomy 0.000 description 17
230000003204 osmotic effect Effects 0.000 description 17
235000002639 sodium chloride Nutrition 0.000 description 17
238000004113 cell culture Methods 0.000 description 16
239000003380 propellant Substances 0.000 description 14
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
230000004941 influx Effects 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 12
230000001965 increasing effect Effects 0.000 description 11
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 10
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 10
102100040247 Tumor necrosis factor Human genes 0.000 description 10
238000009825 accumulation Methods 0.000 description 10
230000010085 airway hyperresponsiveness Effects 0.000 description 10
239000000306 component Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 10
238000009472 formulation Methods 0.000 description 10
210000004072 lung Anatomy 0.000 description 10
102000003298 tumor necrosis factor receptor Human genes 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
241000700199 Cavia porcellus Species 0.000 description 9
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000001963 growth medium Substances 0.000 description 9
108090000288 Glycoproteins Proteins 0.000 description 8
102000003886 Glycoproteins Human genes 0.000 description 8
239000000427 antigen Substances 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
230000002354 daily effect Effects 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
239000011734 sodium Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
239000012981 Hank's balanced salt solution Substances 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000000172 allergic effect Effects 0.000 description 7
208000010668 atopic eczema Diseases 0.000 description 7
230000007423 decrease Effects 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
239000000523 sample Substances 0.000 description 7
235000000346 sugar Nutrition 0.000 description 7
150000008163 sugars Chemical class 0.000 description 7
206010010904 Convulsion Diseases 0.000 description 6
239000004471 Glycine Substances 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
241000700159 Rattus Species 0.000 description 6
229920005654 Sephadex Polymers 0.000 description 6
239000012507 Sephadex™ Substances 0.000 description 6
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 6
210000000621 bronchi Anatomy 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
238000010828 elution Methods 0.000 description 6
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 6
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 5
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 5
206010020751 Hypersensitivity Diseases 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
206010035664 Pneumonia Diseases 0.000 description 5
206010070834 Sensitisation Diseases 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000001045 blue dye Substances 0.000 description 5
238000001514 detection method Methods 0.000 description 5
229960003699 evans blue Drugs 0.000 description 5
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
108700025647 major vault Proteins 0.000 description 5
239000002609 medium Substances 0.000 description 5
229960002329 methacholine Drugs 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
230000002265 prevention Effects 0.000 description 5
210000002345 respiratory system Anatomy 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
230000008313 sensitization Effects 0.000 description 5
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 5
230000007704 transition Effects 0.000 description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
108010006232 Neuraminidase Proteins 0.000 description 4
102000005348 Neuraminidase Human genes 0.000 description 4
239000001888 Peptone Substances 0.000 description 4
108010080698 Peptones Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
239000000654 additive Substances 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000003698 anagen phase Effects 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
238000011685 brown norway rat Methods 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
235000019404 dichlorodifluoromethane Nutrition 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
239000012528 membrane Substances 0.000 description 4
150000002772 monosaccharides Chemical class 0.000 description 4
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
239000006199 nebulizer Substances 0.000 description 4
235000019319 peptone Nutrition 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000000843 powder Substances 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
239000013598 vector Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
208000009079 Bronchial Spasm Diseases 0.000 description 3
206010006482 Bronchospasm Diseases 0.000 description 3
241000244203 Caenorhabditis elegans Species 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
206010037423 Pulmonary oedema Diseases 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
239000013566 allergen Substances 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
238000012511 carbohydrate analysis Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000001030 gas--liquid chromatography Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000009610 hypersensitivity Effects 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000011068 loading method Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
229960000485 methotrexate Drugs 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
210000001331 nose Anatomy 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
208000005333 pulmonary edema Diseases 0.000 description 3
230000000241 respiratory effect Effects 0.000 description 3
239000006152 selective media Substances 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
230000009466 transformation Effects 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
208000014181 Bronchial disease Diseases 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
101000976075 Homo sapiens Insulin Proteins 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
239000007993 MOPS buffer Substances 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920005372 Plexiglas® Polymers 0.000 description 2
241000288906 Primates Species 0.000 description 2
239000012564 Q sepharose fast flow resin Substances 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000008369 airway response Effects 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
239000001055 blue pigment Substances 0.000 description 2
239000001273 butane Substances 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
239000003729 cation exchange resin Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000011098 chromatofocusing Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
108020001096 dihydrofolate reductase Proteins 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
230000002444 effect on eosinophils Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
208000024711 extrinsic asthma Diseases 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
150000002337 glycosamines Chemical class 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
239000012561 harvest cell culture fluid Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
-1 hydrazine anhydride Chemical class 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
239000002523 lectin Substances 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
239000012533 medium component Substances 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
239000003595 mist Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920001993 poloxamer 188 Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
229960003712 propranolol Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000013074 reference sample Substances 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000004043 responsiveness Effects 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000009423 ventilation Methods 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
VMIPKDTYMMAOCX-UHFFFAOYSA-N 2-aminoacetic acid;3,7-dihydropurin-6-one Chemical compound NCC(O)=O.O=C1NC=NC2=C1NC=N2 VMIPKDTYMMAOCX-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000244188 Ascaris suum Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
239000004243 E-number Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229930183217 Genin Natural products 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
244000070406 Malus silvestris Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
206010029379 Neutrophilia Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010004434 Primatone RL Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010070774 Respiratory tract oedema Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000036428 airway hyperreactivity Effects 0.000 description 1
208000037884 allergic airway inflammation Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
235000021120 animal protein Nutrition 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
210000003123 bronchiole Anatomy 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
BUILWQRVQTVUTH-UHFFFAOYSA-N butanoic acid;2-methoxyphenol Chemical compound CCCC(O)=O.COC1=CC=CC=C1O BUILWQRVQTVUTH-UHFFFAOYSA-N 0.000 description 1
LNHFOFJKSJHYGR-UHFFFAOYSA-N butanoic acid;phenylmethanol Chemical compound CCCC(O)=O.OCC1=CC=CC=C1 LNHFOFJKSJHYGR-UHFFFAOYSA-N 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940023913 cation exchange resins Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000033687 granuloma formation Effects 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000004047 hyperresponsiveness Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003601 intercostal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
108010011519 keratan-sulfate endo-1,4-beta-galactosidase Proteins 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
235000019988 mead Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
VQTGUFBGYOIUFS-UHFFFAOYSA-N nitrosylsulfuric acid Chemical compound OS(=O)(=O)ON=O VQTGUFBGYOIUFS-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
229940066779 peptones Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
108010066381 preproinsulin Proteins 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000006013 primary lung bud formation Effects 0.000 description 1
238000011809 primate model Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000013587 production medium Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
230000004088 pulmonary circulation Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
230000006941 response to substance Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
235000015067 sauces Nutrition 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940087562 sodium acetate trihydrate Drugs 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229940120904 succinylcholine chloride Drugs 0.000 description 1
YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP09539522A 1996-05-08 1997-05-02 ＴＮＦＲ―Ｉｇによる喘息の治療 Pending JP2000510113A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1684296P	1996-05-08	1996-05-08
US60/016,842		1996-05-08
PCT/EP1997/002256 WO1997041895A2 (fr)	1996-05-08	1997-05-02	TRAITEMENT DE L'ASTHME PAR TNFR-Ig

Publications (1)

Publication Number	Publication Date
JP2000510113A true JP2000510113A (ja)	2000-08-08

Family

ID=21779275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP09539522A Pending JP2000510113A (ja)	1996-05-08	1997-05-02	ＴＮＦＲ―Ｉｇによる喘息の治療

Country Status (15)

Country	Link
EP (1)	EP0910413A2 (fr)
JP (1)	JP2000510113A (fr)
KR (1)	KR20000010825A (fr)
CN (1)	CN1233189A (fr)
AR (1)	AR007020A1 (fr)
AU (1)	AU725408B2 (fr)
BR (1)	BR9708928A (fr)
CA (1)	CA2253557A1 (fr)
CO (1)	CO4820397A1 (fr)
HR (1)	HRP970224A2 (fr)
MA (1)	MA24169A1 (fr)
PE (1)	PE70698A1 (fr)
TR (1)	TR199802238T2 (fr)
WO (1)	WO1997041895A2 (fr)
ZA (1)	ZA973843B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006519210A (ja) *	2003-02-28	2006-08-24	アレストレーディングソシエテアノニム	腫瘍壊死因子結合タンパク質の液体製剤
JP2015133980A (ja) *	2004-08-27	2015-07-27	ファイザー・アイルランド・ファーマシューティカルズ	抗アミロイドベータ抗体の製法
JP2020059703A (ja) *	2018-10-03	2020-04-16	エーブイエム・バイオテクノロジー・エルエルシー	免疫除去療法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL136988A0 (en) *	1997-12-29	2001-06-14	Regeneron Pharma	Novel nucleic acid and polypeptide
TR200504220T2 (tr)	1998-12-17	2007-04-24	Biogen Idec Ma Inc.	Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US20040220103A1 (en)	1999-04-19	2004-11-04	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) *	1999-04-19	2001-09-13	Pluenneke John D.	Soluble tumor necrosis factor receptor treatment of medical disorders
CN101600450A (zh)	2006-10-20	2009-12-09	比奥根艾迪克Ma公司	利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en)	2006-10-20	2012-12-25	Biogen Idec Ma Inc.	Compositions comprising variant LT-B-R-IG fusion proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0939121B2 (fr) *	1989-09-12	2007-12-26	AHP Manufacturing B.V.	Protéines liant le TNF
AU670125B2 (en) *	1992-09-15	1996-07-04	Immunex Corporation	Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) *	1993-01-22	1997-11-04	Ontario Cancer Institute	Mutant mouse having a disrupted TNFRp55
CA2119089A1 (fr) *	1993-03-29	1994-09-30	David Banner	Muteines du facteur de necrose tumoral
AU3111995A (en) *	1994-07-22	1996-02-22	F. Hoffmann-La Roche Ag	Pharmaceutical compositions comprising a chimaeric tnf binding protein
US5705364A (en) *	1995-06-06	1998-01-06	Genentech, Inc.	Mammalian cell culture process
IL116436A (en) *	1995-12-18	2006-12-31	Yissum Res Dev Co	Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

1997
- 1997-05-02 EP EP97921849A patent/EP0910413A2/fr not_active Withdrawn
- 1997-05-02 HR HR60/016,842A patent/HRP970224A2/xx not_active Application Discontinuation
- 1997-05-02 AU AU27764/97A patent/AU725408B2/en not_active Ceased
- 1997-05-02 CA CA002253557A patent/CA2253557A1/fr not_active Abandoned
- 1997-05-02 KR KR1019980708961A patent/KR20000010825A/ko not_active Withdrawn
- 1997-05-02 JP JP09539522A patent/JP2000510113A/ja active Pending
- 1997-05-02 CN CN97194455A patent/CN1233189A/zh active Pending
- 1997-05-02 TR TR1998/02238T patent/TR199802238T2/xx unknown
- 1997-05-02 MA MA24590A patent/MA24169A1/fr unknown
- 1997-05-02 WO PCT/EP1997/002256 patent/WO1997041895A2/fr not_active Ceased
- 1997-05-02 BR BR9708928-1A patent/BR9708928A/pt not_active Application Discontinuation
- 1997-05-05 PE PE1997000351A patent/PE70698A1/es not_active Application Discontinuation
- 1997-05-05 ZA ZA9703843A patent/ZA973843B/xx unknown
- 1997-05-06 AR ARP970101876A patent/AR007020A1/es not_active Application Discontinuation
- 1997-05-07 CO CO97024335A patent/CO4820397A1/es unknown

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006519210A (ja) *	2003-02-28	2006-08-24	アレストレーディングソシエテアノニム	腫瘍壊死因子結合タンパク質の液体製剤
JP2015133980A (ja) *	2004-08-27	2015-07-27	ファイザー・アイルランド・ファーマシューティカルズ	抗アミロイドベータ抗体の製法
JP2020059703A (ja) *	2018-10-03	2020-04-16	エーブイエム・バイオテクノロジー・エルエルシー	免疫除去療法
KR20210072039A (ko) *	2018-10-03	2021-06-16	에이브이엠 바이오테크놀로지, 엘엘씨	면역절제 요법
JP7671125B2 (ja)	2018-10-03	2025-05-01	エーブイエム・バイオテクノロジー・エルエルシー	免疫除去療法
KR102902532B1 (ko) *	2018-10-03	2025-12-19	에이브이엠 바이오테크놀로지, 엘엘씨	면역절제 요법

Also Published As

Publication number	Publication date
CA2253557A1 (fr)	1997-11-13
MA24169A1 (fr)	1997-12-31
WO1997041895A2 (fr)	1997-11-13
ZA973843B (en)	1997-11-10
BR9708928A (pt)	2000-05-09
PE70698A1 (es)	1998-11-18
CN1233189A (zh)	1999-10-27
AU2776497A (en)	1997-11-26
KR20000010825A (ko)	2000-02-25
AU725408B2 (en)	2000-10-12
EP0910413A2 (fr)	1999-04-28
WO1997041895A3 (fr)	1998-03-12
HRP970224A2 (en)	1998-04-30
AR007020A1 (es)	1999-10-13
CO4820397A1 (es)	1999-07-28
TR199802238T2 (xx)	1999-02-22

Publication	Publication Date	Title
US8784833B2 (en)	2014-07-22	Prenatal enzyme replacement therapy for hypophosphatasia
Renzetti et al.	1996	Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
EP1941908B1 (fr)	2015-08-19	Agent therapeutique pour maladie de coeur
JPH0770195A (ja)	1995-03-14	糖修飾インターフェロン
TW200932262A (en)	2009-08-01	Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient
EP3747469B1 (fr)	2026-04-15	Agent thérapeutique pour l'asthme contenant un inhibiteur d'il-6
EP1626736B1 (fr)	2020-09-16	Inhibiteur de c1 a demi-vie courte pour les traitements transitoires
US11298353B2 (en)	2022-04-12	Anti-inflammatory composition
JP2000510113A (ja)	2000-08-08	ＴＮＦＲ―Ｉｇによる喘息の治療
EP0337799B1 (fr)	1996-08-07	Lectines 14-bêta-gal de mammifères
JPH11500904A (ja)	1999-01-26	Ｍｐｌリガンド類似体
TW202237634A (zh)	2022-10-01	用於治療ｃｏｖｉｄ－１９之ｄｓｇ２組成物和方法
US5514652A (en)	1996-05-07	Therapy of respiratory tract diseases using basic fibroblast growth factor
US9217018B2 (en)	2015-12-22	HSP70 fusion protein conjugates and uses thereof
KR20230140362A (ko)	2023-10-06	항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물
EP4137507A1 (fr)	2023-02-22	Protéine de fusion recombinante pour la prévention ou le traitement de maladies fibrotiques
MXPA98009301A (en)	1999-07-06	Tnfr-ig for the treatment of a
WO2022054825A1 (fr)	2022-03-17	Médicament pour prévenir ou traiter un symptôme ou un trouble chez un sujet affecté par une infection virale
JP3522798B2 (ja)	2004-04-26	糖修飾蛋白質の製造法
JP3879938B2 (ja)	2007-02-14	抗炎症剤
WO1999024069A1 (fr)	1999-05-20	Medicaments preventifs et therapeutiques pour des affections pulmonaires diffuses
WO2005077399A1 (fr)	2005-08-25	Agent preventif et therapeutique pour une broncho-pneumopathie chronique obstructive
JPH08165243A (ja)	1996-06-25	抗炎症剤
JP4854102B2 (ja)	2012-01-18	抗ｉｌ−８抗体を有効成分として含有する間接的原因に起因する急性肺損傷治療剤
HK1022424A (en)	2000-08-11	Treatment of asthma with tnfr-ig